Investor NewsInvestor RelationsNews
Premier Biomedical Announces Modification of Funding Structure
Withdraws Recent S-1
El Paso, Texas, July 27, 2017 – On July 24, 2017 Premier Biomedical, Inc. (OTCQB: “BIEI“) withdrew its registration statement on Form S-1 in order to modify its funding structure. The equity funding underlying this registration was announced in the April CEO Update Letter.
William A. Hartman, President and CEO of Premier Biomedical stated, “Corporate finance for smaller public companies is complicated and ever-changing. The SEC required revised wording of the funding structure. We work closely with our funding partners, and the rules required that we withdraw the S-1 in order to make agreed-upon changes. We anticipate re-filing in a short period of time.”
For more information please contact:
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.